Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity

Leach, 1996, Enhancement of antitumor immunity by CTLA-4 blockade, Science, 271, 1734, 10.1126/science.271.5256.1734 Garber, 2010, Industry makes strides in melanoma, Nat Biotechnol, 28, 763, 10.1038/nbt0810-763 Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466 Sanderson, 2005, Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma, J Clin Oncol, 23, 741, 10.1200/JCO.2005.01.128 Attia, 2005, Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4, J Clin Oncol, 23, 6043, 10.1200/JCO.2005.06.205 Beck, 2006, Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4, J Clin Oncol, 24, 2283, 10.1200/JCO.2005.04.5716 Downey, 2007, Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade, Clin Cancer Res, 13, 6681, 10.1158/1078-0432.CCR-07-0187 Maker, 2005, Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade, J Immunol, 175, 7746, 10.4049/jimmunol.175.11.7746 Hamid, 2011, A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma, J Transl Med, 9, 204, 10.1186/1479-5876-9-204 Hodi, 2014, Bevacizumab plus ipilimumab in patients with metastatic melanoma, Cancer Immunol Res, 2, 632, 10.1158/2326-6066.CIR-14-0053 Klein, 2009, Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4, Clin Cancer Res, 15, 2507, 10.1158/1078-0432.CCR-08-2424 Kulkarni, 2011, Digital multiplexed gene expression analysis using the NanoString nCounter System, Curr Protoc Mol Biol, Chapter 25, Unit25B.10 RStudio, 2015 Benjamini, 1995, Controlling the false discovery rate: a practical and powerful approach to multiple testing, J R Stat Soc, 57, 289 O'Connor, 2000, Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin, Proc Natl Acad Sci USA, 97, 13103, 10.1073/pnas.240390697 Goga, 2007, Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC, Nat Med, 13, 820, 10.1038/nm1606 Mongroo, 2011, IMP-1 displays cross-talk with K-Ras and modulates colon cancer cell survival through the novel proapoptotic protein CYFIP2, Cancer Res, 71, 2172, 10.1158/0008-5472.CAN-10-3295 Wells, 1999, The C-terminal domain of the Cdc2 inhibitory kinase Myt1 interacts with Cdc2 complexes and is required for inhibition of G(2)/M progression, J Cell Sci, 112, 3361, 10.1242/jcs.112.19.3361 Liu, 2014, The MPS1 family of protein kinases, Annu Rev Biochem, 81, 561, 10.1146/annurev-biochem-061611-090435 Abrieu, 2001, Mps1 is a kinetochore-associated kinase essential for the vertebrate mitotic checkpoint, Cell, 106, 83, 10.1016/S0092-8674(01)00410-X Hardwick, 1996, Activation of the budding yeast spindle assembly checkpoint without mitotic spindle disruption, Science, 273, 953, 10.1126/science.273.5277.953 Ling, 2014, Overexpression of Mps1 in colon cancer cells attenuates the spindle assembly checkpoint and increases aneuploidy, Biochem Biophys Res Commun, 450, 1690, 10.1016/j.bbrc.2014.07.071 Liu, 2013, Phosphorylation of Mps1 by BRAFV600E prevents Mps1 degradation and contributes to chromosome instability in melanoma, Oncogene, 32, 713, 10.1038/onc.2012.94 Daniel, 2011, High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells, Proc Natl Acad Sci USA, 108, 5384, 10.1073/pnas.1007645108 Koch A, Maia A, Janssen A et al, Molecular basis underlying resistance to Mps1/TTK inhibitors. Oncogene 2015; 1–11. Ambrosini, 1997, A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma, Nat Med, 3, 917, 10.1038/nm0897-917 Ryan, 2009, Survivin: a new target for anti-cancer therapy, Cancer Treat Rev, 35, 553, 10.1016/j.ctrv.2009.05.003 Takeuchi, 2005, Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine, Int J Cancer, 117, 1032, 10.1002/ijc.21267 Gradilone, 2003, Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients, J Clin Oncol, 21, 306, 10.1200/JCO.2003.08.066 Alonso, 2004, Progression in cutaneous malignant melanoma is associated with distinct expression profiles, Am J Pathol, 164, 193, 10.1016/S0002-9440(10)63110-0 Chen, 2009, Caspases and inhibitor of apoptosis proteins in cutaneous and mucosal melanoma: expression profile and clinicopathologic significance, Hum Pathol, 40, 950, 10.1016/j.humpath.2008.12.001 Jeon, 2013, Prognostic role of survivin in bladder cancer: a systematic review and meta-analysis, PLoS One, 8, e76719, 10.1371/journal.pone.0076719 Song, 2013, Prognostic value of survivin expression in breast cancer patients: a meta-analysis, Tumour Biol, 34, 2053, 10.1007/s13277-013-0848-2 Shinohara, 2005, Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma, Cancer, 103, 1685, 10.1002/cncr.20951 Liu, 2013, Prognostic value of survivin in patients with gastric cancer: a systematic review with meta-analysis, PLoS One, 8, 1, 10.1371/journal.pone.0083350 Chen, 2008, Survivin as a useful adjunct marker for the grading of papillary urothelial carcinoma, Arch Pathol Lab Med, 132, 224, 10.5858/2008-132-224-SAAUAM Shin, 2001, An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7, Biochemistry, 40, 1117, 10.1021/bi001603q Bolton, 2003, Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation, Mol Biol Cell, 13, 3064, 10.1091/mbc.e02-02-0092 Coumar, 2013, Treat cancers by targeting survivin: just a dream or future reality?, Cancer Treat Rev, 39, 802, 10.1016/j.ctrv.2013.02.002 Pennati, 2007, Targeting survivin in cancer therapy: fulfilled promises and open questions, Carcinogenesis, 28, 1133, 10.1093/carcin/bgm047 Singh, 2014, Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers, Drug Discov Today, 20, 578, 10.1016/j.drudis.2014.11.013 Raetz, 2014, A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leu, J Pediatr Hematol Oncol, 36, 458, 10.1097/MPH.0b013e3182a8f58f Becker, 2012, Survivin-specific T-cell reactivity correlates with tumor response and patient survival: A phase-II peptide vaccination trial in metastatic melanoma, Cancer Immunol Immunother, 61, 2091, 10.1007/s00262-012-1266-9 Stauber, 2007, Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential, Cancer Res, 67, 5999, 10.1158/0008-5472.CAN-07-0494 Barreyro, 2012, Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS, Blood, 120, 1290, 10.1182/blood-2012-01-404699 Cao, 2005, CD83 is preformed inside monocytes, macrophages and dendritic cells, but it is only stably expressed on activated dendritic cells, Biochem J, 385, 85, 10.1042/BJ20040741 Lin, 2014, Soluble CD83 inhibits human monocyte differentiation into dendritic cells in vitro, Cell Immunol, 292, 25, 10.1016/j.cellimm.2014.08.003 Horejsi, 2004, Transmembrane adaptor proteins in membrane microdomains: Important regulators of immunoreceptor signaling, Immunol Lett, 92, 43, 10.1016/j.imlet.2003.10.013 Ueki, 2009, Ubiquitination and downregulation of BRCA1 by ubiquitin-conjugating enzyme E2T overexpression in human breast cancer cells, Cancer Res, 69, 8752, 10.1158/0008-5472.CAN-09-1809 Wu, 2012, Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas, Nat Genet, 44, 251, 10.1038/ng.1102 Swindall, 2013, ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell lines, Cancer Res, 73, 2368, 10.1158/0008-5472.CAN-12-3424 Zhuo, 2011, Emerging role of alpha2,6-sialic acid as a negative regulator of galectin binding and function, J Biol Chem, 286, 5935, 10.1074/jbc.R110.191429 Wang YC, Stein JW, Lynch CL et al, Glycosyltransferase ST6GAL1 contributes to the regulation of pluripotency in human pluripotent stem cells. Sci Rep 2015; 5. Su, 2012, A potential role for the homeoprotein Hhex in hepatocellular carcinoma progression, Med Oncol, 29, 1059, 10.1007/s12032-011-9989-6 Garg, 2016, Survivin: a unique target for tumor therapy, Cancer Cell Int, 16, 49, 10.1186/s12935-016-0326-1 Li, 2005, Nuclear or cytoplasmic expression of survivin: What is the significance?, Int J Cancer, 114, 509, 10.1002/ijc.20768 Haanen, 2015, Toxicity patterns with immunomodulating antibodies and their combinations, Semin Oncol, 42, 423, 10.1053/j.seminoncol.2015.02.011